1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 14,400 | 14,700 | 30.12.25 | |
| 0,000 | 0,000 | 30.12.25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.12.25 | Barclays upgrades Fortrea stock rating to Equalweight on biotech recovery | 1 | Investing.com | ||
| 11.12.25 | Fortrea Holdings Inc: Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 04.12.25 | SCTbio and Fortrea form strategic partnership to accelerate cell therapies | 1 | Investing.com | ||
| 04.12.25 | Fortrea Holdings Inc: SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery | 198 | GlobeNewswire (Europe) | PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global... ► Artikel lesen | |
| 24.11.25 | Fortrea completes debt tender offer, reducing outstanding notes | 3 | Investing.com | ||
| FORTREA Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | Fortrea Holdings Inc: Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand | 1 | GlobeNewswire (USA) | ||
| 20.11.25 | Fortrea Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11.25 | Truist Securities raises Fortrea stock price target to $12 from $7 on Q3 results | 2 | Investing.com | ||
| 05.11.25 | Fortrea Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.11.25 | Fortrea Q3 2025 slides: Strategic initiatives drive stock surge despite earnings miss | 4 | Investing.com | ||
| 05.11.25 | Fortrea Holdings Inc. Q3 Earnings Summary | 1 | RTTNews | ||
| 05.11.25 | Fortrea Holdings reports mixed Q3 results; updates FY25 outlook | 2 | Seeking Alpha | ||
| 05.11.25 | Fortrea Holdings Inc: Fortrea Reports Third Quarter 2025 Results | 145 | GlobeNewswire (Europe) | For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 millionGAAP net loss of $(15.9) millionAdjusted EBITDA of $50.7 millionGAAP and adjusted net (loss) income... ► Artikel lesen | |
| 05.11.25 | Fortrea Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10.25 | Fortrea launches $75.7 million debt tender offer for senior notes | 1 | Investing.com | ||
| 20.10.25 | Fortrea Holdings Inc: Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt | 2 | GlobeNewswire (USA) | ||
| 02.10.25 | Where Fortrea Holdings Stands With Analysts | 10 | Benzinga.com | ||
| 22.09.25 | Fortrea names William Sharbaugh to board of directors | 2 | Investing.com | ||
| 22.09.25 | Fortrea beruft William Sharbaugh in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 22.09.25 | Fortrea Holdings Inc. - 8-K, Current Report | 12 | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 48,600 | -0,31 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| QIAGEN | 38,855 | +0,26 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| AMGEN | 279,60 | -0,20 % | BMY vs AMGN: Which Biotech Stock Is More Resilient Now? | ||
| NOVAVAX | 5,792 | +0,33 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 298,50 | -0,37 % | Dividendenbekanntmachungen (31.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1702 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1802 EUR AGNC INVESTMENT CORP US00123Q1040 0... ► Artikel lesen | |
| ILLUMINA | 114,76 | +0,42 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,600 | +0,87 % | Contrarius Global Equity Fund's Thoughts on CRISPR Therapeutics' (CRSP) Gene Editing Therapy | ||
| AAP IMPLANTATE | 1,290 | -3,01 % | EQS-NVR: aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: aap Implantate AG
aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten... ► Artikel lesen | |
| OCUGEN | 1,266 | +1,08 % | Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? | ||
| SANGAMO THERAPEUTICS | 0,345 | -1,34 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,850 | +0,56 % | Cathie Wood's ARK makes strategic stock moves, buys Intellia and sells Roku | ||
| TEMPUS AI | 53,00 | +0,95 % | How Tempus AI Is Building Scale While Near-Term Risks Persist | ||
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| DEFENCE THERAPEUTICS | 0,440 | +3,04 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| EDITAS MEDICINE | 1,711 | -2,40 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen |
FORTREA HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,36 % bei einem Aktienkurs von 14,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTREA HOLDINGS INC finden Sie auf Wallstreet Online.